EUVIMEDEUVIMED entdecken
Crossref

Eptinezumab for adolescents with chronic refractory headache: A retrospective chart review

Natalia Zorrilla, Amy A Gelfand, Samantha L Irwin iD

Headache: The Journal of Head and Face Pain · 2023

DOI: 10.1111/head.14452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2023. Verfasst von Natalia Zorrilla und 2 weiteren Autor:innen. Beteiligte Einrichtung: UCSF Child and Adolescent Headache Program, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco,…. Hauptthemen laut MEDLINE: Quality of Life, Migraine Disorders. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the safety and efficacy of eptinezumab for the treatment of chronic refractory headache in adolescents.

Background

Chronic refractory headache can lead to school absences and impaired quality of life in adolescents, and currently there are no pharmacologic treatments with level A evidence for headache prevention for this population. While observational data suggest that monoclonal antibodies to calcitonin gene–related peptide or its receptor may be helpful for adolescents who have refractory primary headache disorders, evidence is lacking for the use of eptinezumab.

Methods

This was a single‐center, retrospective chart review. Demographic and headache phenotypic data were collected. Outcome measures included headache intensity and frequency pre‐ and post‐infusion(s), and improvement in function or in associated symptoms. Adverse events were also collected.

Results

Nine patients with chronic migraine and two with new daily persistent headache received a first dose of 100 mg of eptinezumab. All of them had daily headache and nine had continuous headache at baseline. After the first infusion of 100 mg, two patients were no longer having daily headache, one patient stopped having continuous headache, and four patients noted headache intensity reduction. Additionally, one patient described a reduction in nausea and vomiting, and another patient noted improvement in function. Six patients received a second eptinezumab infusion of 100 mg, three had a third one, and one patient had four infusions of 100 mg. After the second infusion, one patient noted reduction in headache frequency, one experienced lower headache intensity, and two described pain “improving.” With the third and fourth infusions, patients continued to report improvement in headache intensity. Subsequent infusions of 300 mg resulted in further reductions in headache frequency and intensity for some patients. Eptinezumab was overall well tolerated.

Conclusion

While this was a small sample, findings suggest that eptinezumab may be a safe and effective treatment for chronic, refractory headache in adolescents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeMigraine DisordersHumansAdolescentRetrospective StudiesHeadacheTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

adolescentcalcitonin gene-related peptide monoclonal antibodieschronic daily headachechronic migrainenew daily persistent headachepediatric

Substanzen

eptinezumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • UCSF Child and Adolescent Headache Program, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.

ORCID-Profile: Samantha L Irwin

Zitieren

APA

Zorrilla, N., Gelfand, A. A., & Irwin, S. L. (2023). Eptinezumab for adolescents with chronic refractory headache: A retrospective chart review. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14452

Vancouver

Zorrilla N, Gelfand AA, Irwin SL. Eptinezumab for adolescents with chronic refractory headache: A retrospective chart review. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14452

BibTeX
@article{Zorrilla2023,
  author = {Zorrilla, Natalia and Gelfand, Amy A and Irwin, Samantha L},
  title = {Eptinezumab for adolescents with chronic refractory headache: A retrospective chart review},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  doi = {10.1111/head.14452}
}
Kostenlos starten →